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Ultra rapid in vivo screening for 
anti-Alzheimer anti-amyloid drugs
Alba Espargaró1, Aina Medina1, Ornella Di Pietro2, Diego Muñoz-Torrero2 & Raimon Sabate1
More than 46 million people worldwide suffer from Alzheimer’s disease. A large number of potential 
treatments have been proposed; among these, the inhibition of the aggregation of amyloid β-peptide 
(Aβ), considered one of the main culprits in Alzheimer’s disease. Limitations in monitoring the 
aggregation of Aβ in cells and tissues restrict the screening of anti-amyloid drugs to in vitro studies in 
most cases. We have developed a simple but powerful method to track Aβ aggregation in vivo in real-
time, using bacteria as in vivo amyloid reservoir. We use the specific amyloid dye Thioflavin-S (Th-S) to 
stain bacterial inclusion bodies (IBs), in this case mainly formed of Aβ in amyloid conformation. Th-S 
binding to amyloids leads to an increment of fluorescence that can be monitored. The quantification of 
the Th-S fluorescence along the time allows tracking Aβ aggregation and the effect of potential anti-
aggregating agents.
Amyloid aggregation is linked to an increasing number of human diseases, including both non-neurologic 
and neurodegenerative disorders1. These human disorders, grouped under the term “conformational diseases”, 
include Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s (HD) diseases, frontotemporal dementia (FTD), 
amyotrophic lateral sclerosis (ALS) or type II diabetes, among others1. Nowadays, more than 46 million people 
worldwide suffer from AD and the number is predicted to exceed 130 million by 20502,3. AD is a multifactorial 
and highly complex process, whose pathogenesis involves multiple mechanisms4. However, the appearance of 
both, amyloid plaques –consequence of the accumulation of amyloid β -peptide (Aβ )– and neurofibrillary tangles 
–mainly formed of hyperphosphorylated forms of tau protein from neuronal microtubules– are the most promi-
nent pathological hallmarks in the brain of AD patients, leading to neuronal cell death and tissue loss throughout 
the brain5. For years it has been discussed which is the main cause of Alzheimer’s disease. Currently Aβ aggrega-
tion is widely accepted to be one of the main culprits of the illness6,7. In this light, in the last few years the search 
for potential inhibitors of amyloid aggregation has become one of the most pursued therapeutic strategies in the 
fight against AD8–11.
A large number of methods to track the amyloid aggregation have been recently proposed12–16. The evaluation 
of potential anti-amyloid drugs is usually hampered by the lack of physiologically relevant methods that can be 
easily implemented in high-throughput screening. Monitoring of amyloid aggregation in cells and tissues suffers 
from important drawbacks arising from low protein concentration, slow aggregation process and low repro-
ducibility17. These limitations have restricted the screening of anti-amyloid compounds to in vitro studies using 
expensive synthetic peptides17. Currently, only a handful of methods, which usually track the amyloid associated 
toxicity in cell lines or the amyloid aggregation in vitro, are used to screen anti-Alzheimer anti-amyloid drugs18–21. 
However, the in vitro Aβ aggregation is far from in vivo conditions. Moreover, the cellular toxicity is not directly 
related to the final amyloid amount, but to the type of amyloid-like aggregates formed during the aggregation 
process. In fact, soluble Aβ oligomers, generated at the early stages of the fibrillation process, are considered the 
primary cytotoxic species1,22–24. Because in vivo amyloid kinetics may provide key information about both the 
amyloid aggregation process, still essentially uncharacterized, and inhibition mechanisms, the development of 
fast, simple, reproducible in vivo methods could represent a breakthrough in the understanding of the amyloid 
aggregation process and eventually in the search for potential anti-Alzheimer anti-amyloid drugs. Bacteria rep-
resent a simple but quantitative method, which will always be closer to the in vivo conditions in mammals than 
in vitro and toxicity assays.
The proposed method uses bacteria as an in vivo reservoir to track in real-time amyloid aggregation kinetics. 
The use of prokaryotic systems as microbial cell factories in the production of recombinant proteins has become 
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an essential tool for the biotechnological industry and biomedical research25. Over-expression of amyloid-prone 
proteins in bacteria entails the formation of insoluble protein aggregates called inclusion bodies (IBs)26,27. 
Compelling evidence has unequivocally demonstrated that recombinant amyloid-prone proteins are folded in 
amyloid-like conformations into IBs26,27. Indeed, IBs formed after the over-expression in bacteria of the major 
Aβ peptides, namely Aβ 40 and Aβ 42, have been shown to display amyloid-like structures28. In this context, we 
have recently shown the usefulness of the amyloid specific dye Thioflavin-S (Th-S) to track the amyloid deposits 
of different amyloid-prone proteins in bacteria29,30. The facts that (1) Th-S staining of amyloid-like structures 
leads to an increase in it specific fluorescence –when excited under blue light– which can be easily monitored 
without interfering the bacteria growth and (2) Th-S crosses membranes and penetrates into the cell without 
affecting amyloid aggregation, make Th-S the dye of choice for tracking amyloid aggregation in vivo29,30. Despite 
the noticeable applicability of our previously reported methods in anti-amyloid drug discovery, they do not allow 
the quantification of the amyloid amount in cell or the amazing possibility to track in-real time the in vivo aggre-
gation of amyloid-prone proteins. Herein, we describe an alternative method that compiles the capacity of bacte-
ria as physiologically relevant models for the in vivo study of amyloid aggregation and the ability of Th-S to stain 
amyloid structures, thereby enabling the quantitative in vivo screening of anti-amyloid drugs, both in kinetic and 
thermodynamic terms. Importantly, the proposed method allows to track simply but effectively the inhibitory 
capacity of potential anti-amyloid drugs at each stage of the aggregation process, providing direct information of 
the behavior of each inhibitor along the aggregation time.
Results and Discussion
Aβ 40 and Aβ 42 are the main components of the senile plaques. However, the physicochemical properties of Aβ 40 
e.g. higher solubility and lower aggregation propensity relative to Aβ 42 – have made it the peptide of choice in 
kinetic in vitro assays. Because the over-expression of Aβ 42 in bacteria results in the formation of a large amount 
of oligomeric species28, we propose here to use the Aβ 40 variant, which does not form oligomers in bacteria28, to 
screen the anti-aggregation effect of two potential inhibitors of the amyloid fibril polymerization. However, Aβ 42 
aggregation kinetics have been additionally analyzed to assess the effect of the inhibitors in both Aβ variants. We 
show herein the high efficiency and performance of our ultra rapid in vivo screening method for anti-Alzheimer 
anti-amyloid drugs in bacteria over-expressing Aβ 40 and Aβ 42 in the presence or absence of two potential inhib-
itors of Aβ aggregation; DP-128, a chlorotacrine-based inhibitor of Aβ 42 and tau aggregation, and apigenin, a 
natural flavone with demonstrated activity against insulin amyloids (structures in Supplementary Fig. 1)31,32. In 
order to show the differences in the Th-S spectra of bacteria over-expressing or not Aβ (viz. with or without IBs 
containing Aβ in amyloid conformation, respectively) as well as the potential tracking of amyloid formation in 
vivo, we measured the kinetics of induced (over-expressing Aβ 40) and non-induced (non-overexpressing Aβ 40) 
bacterial cultures in the presence and absence of inhibitors, by tracking the Th-S fluorescence spectra along the 
time in a range from 460 to 600 nm, exciting at 440 nm. Under these conditions, the formation of Aβ 40 and Aβ 42 
IBs with time leads to unequivocal changes between non-induced and induced cultures as a consequence of 
the Th-S staining of IBs (Supplementary Fig. 2). In the non-induced samples the maximal fluorescence of Th-S 
as a consequence of the interaction with bacteria is at ~523 nm (Supplementary Fig. 2a,c,e). However, in the 
induced samples without inhibitor we observe the progressive appearance of a new peak (non-observable in the 
non-induced samples) at ~495 nm, arising from the Th-S binding to gradually formed Aβ IBs (Supplementary 
Fig. 2b); Interestingly, this peak is reduced in the induced samples in the presence of inhibitors as a result of the 
reduction of Aβ aggregation (Supplementary Fig. 2d,f). When the spectra of non-induced cultures were sub-
tracted from those of Aβ over-expressing cultures along the time-course, we obtained the typical amyloid band 
displaying a maximal peak at ~485 nm (Fig. 1 and Supplementary Fig. 3). Importantly, we observed a diminution 
of the amyloid band in the samples with inhibitor (Fig. 1b,c) in comparison with the samples without inhibitor 
(Fig. 1a); with this fact being indicative of a reduction of the amyloid structures in the bacterial cells that grow in 
the presence of inhibitors (Supplementary Fig. 3a). The relative fluorescence data at 485 nm can be transformed 
into amyloid concentration. To quantify the obtained peaks we built a Th-S–Aβ 40 standard curve using in vitro 
preformed Aβ 40 amyloid fibrils (Supplementary Fig. 4b,c)33. Then, the Aβ 40 amount in amyloid-like confor-
mation that is present in IBs can be easily and precisely quantified by simple interpolation of the Th-S relative 
fluorescence data from the time-course reaction at 485 nm in the standard curve (Fig. 2). In order to discard 
Figure 1. Th-S relative fluorescence of the amyloid band along the time-course. (a) In the absence of 
inhibitor. (b) In the presence of 10 μM DP-128. (c) In the presence of 10 μM apigenin. The dotted arrows show 
the maximal amyloid peak ~485 nm. In green and red, the initial (0 min) and final (480 min) time-course. Th-S 
relative fluorescence measurements were performed in triplicate and the standard errors were less than 5%.
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differences in bacterial growth and protein expression level as a consequence of the presence of the inhibitors, 
we evaluated Aβ 40 concentration along the time (by tricine-SDS-PAGE) (Fig. 3a and Supplementary Fig. 5) and 
bacterial growth (by OD at 600 nm) in the presence and absence of each inhibitor (Fig. 3b). The SDS-PAGE band 
corresponding to Aβ peptide has been previously identified by western blotting using 6E10 Aβ antibody28. As 
shown in Fig. 3a,b, no significant differences in expression and growth patterns were observed, hence confirming 
that these inhibitors do not interfere with these parameters. In the case that the potential drug interfered with 
these parameters the differences would have to be taken into account to normalize further amyloid aggrega-
tion kinetics. Complementarily, we checked the Aβ 40 distribution between soluble and insoluble fractions (i.e. 
between soluble and aggregated Aβ 40) at the end-point of kinetics. As shown in Fig. 3c, Aβ 40 is present almost 
exclusively in the insoluble fraction. Interestingly, no significant differences in the Aβ 40 distribution between 
soluble and insoluble fractions were observed in the absence and presence of inhibitors (Fig. 3c).
Amyloid kinetics can be mechanistically described as a nucleation dependent polymerization process34, 
wherein initially soluble species are associated forming nuclei in a thermodynamically disfavored stage, with 
these preformed nuclei acting as templates of soluble species that are favorably added to form first amyloid fibrils 
and eventually mature fibers34,35. In vitro and in vivo systems are being extensively used for exploring and mod-
eling the kinetics of Aβ aggregation, which is one of the most important target for drug discovery and devel-
opment13,15,35–45. Within a wide range of models, this kind of processes can be mathematically addressed as an 
autocatalytic reaction, considering the nucleation (kn) and elongation (ke) constants of the process, and associated 
kinetic times: lag time of the thermodynamically disfavored phase (t0), maximal growth (t1/2) and final time of 
the amyloid aggregation (t1)35. When the obtained data from the aggregation kinetics are analyzed using the 
autocatalytic model, the effect of each inhibitor can be easily quantified in kinetic and thermodynamic terms. 
Thus, kn displays reductions of ~1.7 and ~1.5-fold in the presence of DP-128 and apigenin, respectively, leading to 
elongations of ∼ 25% in t0 for both inhibitors. Reductions in kn rate denote an inhibitory action in the nucleation 
phase, i.e. the formation of amyloid nuclei is partially hindered as a consequence of the presence of the inhibitor 
delaying the appearance of the first amyloid-like species. In contrast, keapp is increased ∼ 1.6 and ∼ 2-fold in the 
presence of DP-128 and apigenin, respectively, but without significant changes in t1/2 and t1. Increments in the 
keapp should be interpreted as an increment in the elongation rate, i.e. as an acceleration of the elongation of the 
fibrils. However, this is only due to the fact that keapp has been calculated using the final Aβ 40 amyloid amount 
of each aggregation kinetic, it being 6.0, 4.0, and 3.2 μM for the control without inhibitor, DP-128, and aginenin, 
respectively (Table 1). In brief, at a same elongation rate, the less monomers are available to form fibrils, the 
sooner the reaction ends. However, as shown in Table 1, when [Aβ 40fibrils]·ke is calculated similar ke are obtained 
(~0.017 min−1). In consequence, t1/2 and t1 remain essentially unaltered in the presence of inhibitors. In kinetic 
terms, the obtained data suggest that both inhibitors act by delaying the amyloid aggregation and hindering the 
nuclei formation. In addition, the final amounts of amyloid-like Aβ 40 were reduced in 33 and 46% for DP-128 
and apigenin, respectively (Fig. 2 and Table 1). The obtained data show that DP-128 and apigenin act essentially 
in the nucleation whereas elongation is almost not altered. However, both inhibitors led to a remarkable reduction 
in the final amount of amyloid aggregates under our experimental conditions. As shown in Supplementary Fig. 6 
Th-S staining could be directly assessed by optical fluorescence microscopy. Whereas non-induced cells do not 
show any Th-S fluorescence (Supplementary Fig. 6a), induced cells in the absence of inhibitor (Supplementary 
Fig. 6b) display high fluorescence as a consequence of Th-S staining so that the Aβ 40 IBs can be easily detected. 
In the presence of active inhibitors the fluorescence is drastically reduced (Supplementary Fig. 6c,d) denoting a 
reduction of amyloid amount in IBs. Interestingly, similar inhibitions are obtained when the Aβ 42 variant has 
been tested. Indeed, as shown in Supplementary Fig. 7, DP-128 and apigenin lead to inhibitions of Aβ 42 aggre-
gation of 28 and 45%, respectively.
In summary, the proposed method, directly tracking the Th-S relative fluorescence in bacterial cells, allows the 
in vivo monitoring of the activity of potential anti-amyloid drugs in an extremely short time (< 24 h), shedding 
Figure 2. Aβ40 amyloid concentration along the time-course kinetics and amyloid concentration at end-
point of the time-course. In black, red and green, in the absence (control) and presence of 10 μM DP-128 and 
apigenin, respectively. Aβ 40 concentrations were measured in triplicate and the standard errors were less than 5%.
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Figure 3. Aβ40 expression and bacterial growth in the absence and presence of inhibitors. (a) Protein 
expression in bacterial cultures along the time tracked by tricine-SDS-PAGE. (b) Bacterial growth monitored by 
optical density at 600 nm (OD600); the ODs were measured in triplicate and the standard errors were less than 
5%. In black, red and green, in the absence (control) and presence of 10 μM DP-128 and apigenin, respectively. 
Solid and dashed lines show induced and non-induced cultures, respectively. (c) Aβ 40 distribution in bacteria: 
Total (T), soluble (S) and insoluble (I) fraction of Aβ 40 at end-point of kinetics.
Inhibitor Without DP-128a Apigenina
kn (106·min−1) 200.5 118.5 135.0
keapp (M−1·min−1)b,c 2723.5 4427.8 5336.5
[Aβ 40fibrils]·ke (min−1) 0.0164 0.0179 0.0173
t0 (min) 112.0 140.6 144.3
t1/2 (min) 268.3 279.4 279.4
t1 (min) 424.5 418.3 414.6
[Aβ 40fibrils] (μM)d 6.0 4.0 3.2
Table 1.  Kinetic and thermodynamic parameters of Aβ40 amyloid aggregation. aInhibition parameters at 
10 μM of inhibitor. bSince Aβ 40 concentration is not constant along the aggregation process, the ke are apparent. 
cIn order to calculate the keapp, the final Aβ 40 amyloid amount of each aggregation kinetic has been considered. 
dAβ 40 concentration in amyloid conformation at end-point of the time-course.
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light on the inhibitor behavior and enabling the determination of IC50 values if different inhibitor concentrations 
are used. Interestingly, the present method allows simultaneous acquisition of the kinetic and thermodynamic 
parameters of each process, enabling the fast classification of inhibitors by accurately quantifying their inhibi-
tory activity in each stage of the amyloid aggregation process. The reported method could be easily adapted to 
real-time micro-plate readers, thereby enabling high-throughput screenings with the simultaneous tracking of up 
to 1536 samples. Importantly, the method can be potentially used for the screening of anti-amyloid drugs against 
all conformational diseases by simply changing the amyloid-prone protein over-expressed in bacteria.
Methods
Chemicals and bacterial media. DP-128, N-{8-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]
octyl}-5-(4-chlorophenyl)-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridine-9-carboxamide, was prepared as pre-
viously reported31. The natural flavone apigenin (4′,5,7-trihydroxyflavone) and all other general chemicals were 
purchased from Sigma-Aldrich. Compounds for bacterial media were purchased from Pronadisa. M9 minimal 
medium; For 100 mL: 10 mL salts 10 × (0.68 g Na2HPO4, 0.30 g KH2PO4, 0.05 g NaCl, 0.10 g NH4Cl), 0.2 mL 1 M 
MgSO4, 0.2 mL 50 mM CaCl2, 2.5 mL 20% glucose and 87.1 mL H2O.
Preparation of soluble Aβ40 peptide. Aβ 40 (trifluoroacetic acid salt) was obtained from Bachem. A 
stock solution was prepared by dissolving 1 mg of Aβ 40 in 0.5 mL of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), 
which had been dried at 4 °C over molecular sieves Type 4A and then centrifuged (15,000 g for 15 min) to remove 
molecular sieve dust. The solution was incubated under stirring at room temperature for 1 h in sealed vials, 
bath-sonicated for 30 min, and stirred for an additional hour at room temperature. Then, the solution was kept at 
4 °C for 30 min to avoid solvent evaporation when aliquoting. Once the sample was aliquoted, HFIP was removed 
by evaporation under a gentle stream of nitrogen, leaving a slightly yellow film. The samples of soluble Aβ 40 pep-
tide were frozen at − 80 °C. Frozen aliquots were re-suspended in 50 μL of anhydrous dimethyl sulfoxide (DMSO) 
and bath-sonicated for 10 min. Sonication was crucial to remove any traces of un-dissolved seeds that may resist 
solubilization. Aliquots of Aβ were re-suspended in 950 μL of PBS at pH 7.4. The final buffer contained 5% (v/v) 
DMSO46. The final concentration of Aβ was adjusted by UV absorbance considering a molar absorptivity of 
1490 mol−1·dm3·cm−1 at 280 nm using a UV-2401 PC UV-Vis spectrophotometer from Shimadzu.
In vitro Aβ40 aggregation. Aggregation of initially soluble Aβ 40 was carried out for 48 h at 37 °C and 
1,400 rpm using a Thermomixer from Eppendorf. The amount of insoluble amyloid fibrils at the end-time of the 
reaction was quantified after centrifugation at 14,000 g for 30 min. As previously observed, the insoluble fraction 
represented 90% of the initial Aβ 40, remaining 10% as soluble33. This correction was taken into account in the 
determination of the amyloid stock concentration.
The standard curve was built by sequential dilution of the stock solution. The relative fluorescence of the sam-
ples was determined using a final concentration of Th-S of 250 μM and 75, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.8, 0.4 
and 0 μM of in vitro fibrils of Aβ 40 preformed under the same conditions as the kinetics.
Cloning and expression of Aβ peptide. Escherichia coli competent cells BL21 (DE3) were transformed 
with the pET28a vector from Novagen carrying the DNA sequence of Aβ 40 or Aβ 42. Because of the addition 
of the initiation codon ATG in front of gene, the over-expressed peptide contains an additional methionine 
residue at its N terminus (MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV for Aβ 40 and 
MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA for Aβ 42). For overnight culture prepara-
tion, 10 mL of M9 minimal medium containing 50 μg·mL−1 of kanamycin were inoculated with a single colony 
of BL21 (DE3) bearing the plasmid to be expressed at 37 °C. For expression of the Aβ peptide, 100 μL of over-
night culture (providing a starting OD600 of 0.1–0.2) was used to inoculate 9.9 mL of fresh M9 minimal medium 
containing kanamycin and Th-S for a final concentration of 50 μg·mL−1 and 250 μM, respectively, and 10 μL of 
the inhibitors in 10 mM stock solution DMSO. Note that in the samples without inhibitor 10 μL of DMSO had 
to be added. Then, bacterial cultures were grown at 37 °C and 250 rpm. When OD600 reached ~0.7, 10 μL of iso-
propyl 1-thio-β -D-galactopyranoside (IPTG) at 1 M were added to induce Aβ over-expression. Then, 200 μL of 
sample were collected every 30 min during all time-course of the kinetics and fluorescence and absorbance were 
determined.
As “positive control” we used induced bacterial cells bearing Aβ plasmid (over-expressing Aβ ) without inhib-
itor, displaying the maximal potential aggregation of the Aβ peptide in bacteria. As “negative control” we used 
non-induced bacterial cells bearing Aβ plasmid without inhibitor, showing the minimal expression of Aβ in the 
cells. However, to discard potential effects of the inhibitor in the Th-S signal (e.g. when the inhibitor also displays 
certain fluorescence in Th-S range), a “negative control” of each inhibitor was performed using non-induced 
bacterial cells bearing Aβ plasmid in the presence of each inhibitor. Importantly, this is highly useful to discard 
potential effects of the inhibitors in the cell growth (by OD600).
Quantification of Aβ40 in amyloid conformation in bacterial cells. Because non-induced cultures 
display relative fluorescence in the Th-S emission range (460–600 nm) when exciting at 440 nm (Supplementary 
Fig. 2a,c,e), these spectra would have to be removed from Th-S fluorescence spectra of induced cultures 
(Supplementary Fig. 2b,d,f) to quantify the amount of Aβ 40 in amyloid-like conformation. Since OD600 are 
known at each kinetic time, induced cultures (over-expressing Aβ 40) could be easily corrected by subtracting the 
spectrum of non-induced cells with similar OD600, thus obtaining Th-S amyloid band (Fig. 1).
As shown in Supplementary Fig. 4b,c, the standard curve of in vitro Aβ 40 fibrils shows a linear relationship 
between Aβ 40 fibril concentration and Th-S relative fluorescence at 485 nm (the maximum of the amyloid band). 
The interpolation of Th-S fluorescence of in vivo kinetics at 485 nm in the standard curve allows the easy transfor-
mation from fluorescence into amyloid concentration.
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Aβ40 expression levels in bacterial cells. Aβ 40 concentration in cell cultures in the presence and 
absence of inhibitor was assessed by tricine-SDS-PAGE. 300 μL of induced bacterial cells were collected each 
hour during all time-course of the kinetics. Then, the samples were concentrated by gentle centrifugation obtain-
ing OD600 of 8. 30 μL of concentrated sample were added to 4× loading buffer (250 mM Tris-HCl pH 6.8, 10% 
SDS, 0.008% Bromophenol Blue, 40% glycerol and 2.86 M β -mercaptoethanol). Finally, the samples were placed 
at 95 °C for 10 min. Denatured samples were analyzed using 16% tricine SDS-PAGE (Fig. 3a and Supplementary 
Fig. 5).
In order to check the Aβ 40 aggregation in bacteria, soluble and insoluble protein fractions were required. 
Then, 1 mL of concentrated sample from the end-point of each kinetic was pelleted by centrifugation at 
14,000 rpm (20 min, 4 °C). The pellet containing the cells was frozen at −80 °C for at least 2 h. Then, cell pellets 
were re-suspended in 1 mL of phosphate buffer saline 1× (PBS) and sonicated using a SONICS Vibra CellTM from 
Vibra-Cell-Sonics & Materials, Inc. at 30% during 1 min (with intervals of 1 seg sonication/0.5 seg stand-by). 
Soluble and insoluble fractions were separated by centrifugation at 14,000 rpm (20 min, 4 °C). The insoluble frac-
tion was re-suspended in 1 mL PBS 1 ×. Finally, the samples were analyzed by tricine-SDS-PAGE (Fig. 3c).
Thioflavin-S (Th-S) Steady-State Fluorescence. Relative fluorescence of Th-S binding to Aβ was 
checked using an Aminco Bowman Series 2 luminescence spectrophotometer from Aminco-Bowman with an 
excitation wavelength of 440 nm and emission range from 460 to 600 nm. The emission at 485 nm was recorded 
for further determination of the amyloid-like concentration. Excitation and emission slit widths of 4 nm were 
used and spectra were acquired at 1 nm intervals and 500 nm·min−1 rates and 875 V47. Importantly, in order to 
compare the obtained data, the voltage must always be known and not changed.
Aggregation assay analysis. The amyloid aggregation in bacteria may be studied as an autocatalytic reac-








{exp[(1 ) ] 1}
1 exp[(1 ) ] (1)
under the boundary condition of t = 0 and f = 0, where k = kea (when a is the protein concentration) and  ρ repre-
sents the dimensionless value to describe the ratio of kn to k. By non-linear regression of f against t, values of ρ and 
k are obtained, and from them the rate constants, ke (elongation constant) and kn (nucleation constant)35. Note 
that because the concentration of Aβ is not constant in the bacterial cells during the protein over-expression, we 
have arbitrarily considered as a the Aβ concentration of the final time-course, obtaining apparent values for ke, 
which allow quantitative comparison of kinetics. The extrapolation of the linear portion of the sigmoid curve to 
abscissa (f = 0), and to the highest ordinate value of the fitted plot, afforded two values of time (t0 and t1), which 
correspond to the lag time and to the end-time reaction. The time at which half of the protein was aggregated (i.e., 
when f = 0.5) was considered the time of half-aggregation (t1/2)35.
Optical fluorescence microscopy. Bacterial cells overexpressing Aβ 40 were incubated 1 h with 125 μM of 
Th-S. Th-S was removed by centrifugation and the cells were re-suspended in PBS twice and placed on a micro-
scope slide. Th-S fluorescence was detected using a Leitz DMIRB microscope under UV light using a GFP filter 
(excitation filter BP480/40 and emission filter BP527/30)48.
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